Skip to main content
Top
Published in: BMC Gastroenterology 1/2022

Open Access 01-12-2022 | Metastasis | Case report

Cholangiocarcinoma presenting as dysphagia and misdiagnosed as gastritis: a case report

Authors: Chao Wang, Baoyue Zhang, Runmei Peng, Zan Zuo, Hongzhong Cheng, Jun Zhu, Tianxing Chen, Zhengji Song

Published in: BMC Gastroenterology | Issue 1/2022

Login to get access

Abstract

Background

Heterotopic tumor is a rare disease. Thus far, no cases of heterotopic cholangiocarcinoma have been reported in the world. Cholangiocarcinoma mainly metastasizes by direct invasion, and it can lead to liver metastasis in its advanced stage. There were few clinical cases of gastric metastasis in advanced tumors, mainly seen in breast cancer, lung cancer, liver cancer, malignant melanoma, choriocarcinoma, and hematological tumors. Metastases of cholangiocarcinoma to the stomach also are exceptionally rare.

Case presentation

A 58-year-old man was admitted to the hospital because of difficulty swallowing for one year. Upon gastroscopy, we found the tumor at the region of the cardia and gastric fundus. Macroscopical appearance of the tumor suggested its malignant nature. Computed tomography (CT) findings showed that the wall of the cardia, fundus, and stomach body were thickened, suggesting a tumor. Because the patient had obvious difficulty swallowing, we invited cardiothoracic surgeons for consultation. They considered that the patient had definite mechanical obstruction in the lower esophagus; hence, they performed an operation. Immunohistochemical staining revealed low-to-medium differentiated adenocarcinoma (containing mucinous adenocarcinoma components) of biliary origin.

Conclusions

We highlight the importance of the endoscopic biopsy of gastric tumor. However, when its results are inconsistent with the clinician’s judgment, further examination is required. Endoscopic ultrasonography and enhanced CT may be a good choice. If necessary, on the premise of patient acceptance, the diagnosis could be confirmed after surgical excision. Here we report a case of a patient with heterotopic cholangiocarcinoma in the gastric fundus. The most common tissue ectopias in the digestive tract include esophagogastric gastric mucosal ectopia, duodenal gastric mucosal ectopia, and gastric mucosal small intestinal ectopia. Thus far, there have been no reports of ectopic cholangiocarcinoma and associated cancer in the stomach. In addition, metastases of cholangiocarcinoma to the stomach are also exceptionally rare, and most of them are due to a direct invasion. The discovery of the primary lesion is an important clue for the reliable diagnosis in such cases.
Literature
1.
go back to reference Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73.CrossRef Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224(4):463–73.CrossRef
2.
go back to reference Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2(2):58–64.CrossRef Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol. 2010;2(2):58–64.CrossRef
3.
go back to reference Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345-348.CrossRef Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345-348.CrossRef
4.
go back to reference Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17(1):13.CrossRef Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012;17(1):13.CrossRef
5.
go back to reference Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.CrossRef Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.CrossRef
6.
go back to reference Ghoshal UC, Sachdeva S, Sharma A, Gupta D, Misra A. Cholangiocarcinoma presenting with severe gastroparesis and pseudoachalasia. Indian J Gastroenterol. 2005;24(4):167–8.PubMed Ghoshal UC, Sachdeva S, Sharma A, Gupta D, Misra A. Cholangiocarcinoma presenting with severe gastroparesis and pseudoachalasia. Indian J Gastroenterol. 2005;24(4):167–8.PubMed
7.
go back to reference Leung VK, Kan PS, Lai MS. Cholangiocarcinoma presenting as pseudoachalasia and gastroparesis. Hong Kong Med J. 2003;9(4):296–8.PubMed Leung VK, Kan PS, Lai MS. Cholangiocarcinoma presenting as pseudoachalasia and gastroparesis. Hong Kong Med J. 2003;9(4):296–8.PubMed
8.
go back to reference Lai S. A human mode of intestinal type gastric carcinoma. Med Hypotheses. 2019;123:27–9.CrossRef Lai S. A human mode of intestinal type gastric carcinoma. Med Hypotheses. 2019;123:27–9.CrossRef
9.
go back to reference Sciarra A, Hessler R, Godat S, Fraga M, Dromain C, Duran R, Halkic N, Sempoux C. Heterotopic gastric mucosa in a duplication cyst of the common hepatic duct mimicking cholangiocarcinoma. Int J Surg Pathol. 2018;26(1):84–8.CrossRef Sciarra A, Hessler R, Godat S, Fraga M, Dromain C, Duran R, Halkic N, Sempoux C. Heterotopic gastric mucosa in a duplication cyst of the common hepatic duct mimicking cholangiocarcinoma. Int J Surg Pathol. 2018;26(1):84–8.CrossRef
10.
go back to reference Kim Y, Jung MJ, Shin SJ. Heterotopic gastric mucosa in the common bile duct with cholangiocarcinoma. Int J Surg Pathol. 2018;26(8):745–8.CrossRef Kim Y, Jung MJ, Shin SJ. Heterotopic gastric mucosa in the common bile duct with cholangiocarcinoma. Int J Surg Pathol. 2018;26(8):745–8.CrossRef
11.
go back to reference Imamura N, Kusashio K, Yasutomi J, Matsumoto M, Suzuki T, Iida A, Fushimi K, Furukawa A, Konishi T, Harano R, et al. A rare case of gastric metastasis from cholangio carcinoma. Gan To Kagaku Ryoho. 2019;46(13):2470–2.PubMed Imamura N, Kusashio K, Yasutomi J, Matsumoto M, Suzuki T, Iida A, Fushimi K, Furukawa A, Konishi T, Harano R, et al. A rare case of gastric metastasis from cholangio carcinoma. Gan To Kagaku Ryoho. 2019;46(13):2470–2.PubMed
Metadata
Title
Cholangiocarcinoma presenting as dysphagia and misdiagnosed as gastritis: a case report
Authors
Chao Wang
Baoyue Zhang
Runmei Peng
Zan Zuo
Hongzhong Cheng
Jun Zhu
Tianxing Chen
Zhengji Song
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2022
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-022-02156-6

Other articles of this Issue 1/2022

BMC Gastroenterology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine